Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR )

41.14 -0.01 (-0.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 4 5 Next >
IPO watch 2024: Which new stocks will hit the market?
Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now
It has genuine struggles ahead, but it has some actual value in hand as well. 
Via The Motley Fool
2 Biotech Stocks That Could Soar in December
These two biotechs have important catalysts coming up in December. 
Via The Motley Fool
What 6 Analyst Ratings Have To Say About Structure Therapeutics
Via Benzinga
4 Analysts Have This to Say About Structure Therapeutics
Via Benzinga
7 Small-Cap Stocks That Wall Street Loves for Good Reason
The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading 
Via InvestorPlace
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Despite a Wednesday tumble, the major indexes are right at 2023 highs. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Nasdaq Gains 100 Points; Biomerica Shares Spike Higher
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded up 0.01% to 37,307.40 while the NASDAQ rose 0.71% to 14,919.07.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises 3%; US Housing Market Index Increases In December
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Monday. The Dow traded up 0.14% to 37,356.29 while the NASDAQ rose 0.25% to 14,851.19. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Novo Nordisk's Potential Obesity Drug Rival Structure Therapeutics Stock Tanking Today?
Structure Therapeutics Inc (NASDAQ: GPCR) shares are trading lower after the company provided a comprehensive development program update for its highly selective oral GLP-1  
Via Benzinga
Dow Gains Over 50 Points; Nippon Steel To Acquire U. S. Steel
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.15% to 37,362.28 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
Structure Stock Takes A Brutal Beating After Obesity Drug Trails Lilly's Leader
The company is hoping to break into the pack with an oral GLP-1 agonist. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
From Structure Therapeutics Inc.
Via GlobeNewswire
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider. 
Via InvestorPlace
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks. 
Via InvestorPlace
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Should You Still Buy the Nasdaq's Best-Performing October Stocks?
Last month's big winners were tricky to handle due to the amount of speculation investors were willing to do with them. 
Via The Motley Fool
Top 5 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2023
Via Benzinga
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
BMO Capital Maintains Outperform Rating for Structure Therapeutics: Here's What You Need To Know
Via Benzinga
Why Shares of Structure Therapeutics Are Up Monday
The stock climbed for the second straight day after the company reported positive trial data for its weight-loss therapy drug. 
Via The Motley Fool
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Shares of Structure Therapeutics Are Soaring on Friday
The company reported positive results from an early-stage clinical trial for its weight-loss therapy candidate. 
Via The Motley Fool
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.